Section 1 Short title
This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.
Adding Zika Virus to the FDA Priority Review Voucher Program Act
AN ACT
To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.
Sec. 2 Expanding tropical disease product priority review voucher program to encourage treatments for Zika Virus Disease
Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—
by redesignating subparagraph (R) as subparagraph (S);
in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and
by inserting after subparagraph (Q) the following:
“(R) Zika Virus Disease.”